Walasa Tablet
Mesalazine
400mg
Wallace Pharmaceuticals Pvt Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 10.81 NPR |
Indications
Walasa Tablet is used for:
Ulcerative colitis, Hairy cell leukaemia
Adult Dose
Oral
Ulcerative colitis
Adult: Dose is dependant on preparation and brand used.
Acute attack: Initially, up to 4 g daily in 2-4 doses;
Maintenance of remission: 2 g daily in 2 divided doses.
Child Dose
Oral
Ulcerative colitis
5-12 yr: Acute attack: 15-20 mg/kg (max: 1 g) tid;
Maintenance of remission: 10 mg/kg (max: 500 mg) 2-3 times daily.
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<20 Avoid.
Administration
Contra Indications
Hypersensitivity to mesalazine, salicylates and sulfasalazine. Severe impaired renal (CrCl < 20 ml/min) or hepatic function. Children <2 yr.
Precautions
Mild to moderate impaired renal or hepatic function (test serum creatinine before treatment, every 3 mth for 1st yr, every 6 mth for next 4 yr, then annually). Elderly; active peptic ulcer; pregnancy, lactation; patients predisposed to pericarditis or myocariditis. Counsel patients to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise during treatment; perform blood count and stop treatment if blood dyscrasias suspected. Counsel patients taking delayed release tablets to report repeatedly unbroken or partially broken tablets in their faeces. Pyloric stenosis may delay release into colon.
Pregnancy-Lactation
Interactions
Do not give with lactulose or other drugs which lower pH for they prevent release of mesalazine. May decrease digoxin absorption.
Adverse Effects
Side effects of Mesalazine :
Abdominal pain (if new abdominal pain - consider pancreatitis); headache, nausea; flu; fatigue; fever, rash; sore throat; diarrhoea; joint pain; dizziness; bloating; back pain; haemorrhoids; itching; rectal pain, constipation; hair loss; intolerance syndrome; peripheral oedema; UTI; myocarditis, pre-existing pericarditis; pancreatitis; nephritis; hepatitis; lupus-like syndrome; alopecia; myalgia, arthralgia; increased liver enzyme values.
Potentially Fatal: Blood dyscrasias, aplastic anaemia, agranulocytosis; renal toxicity.
Mechanism of Action
Mesalazine is considered to be the active moiety of sulfasalazine. The mechanism of action is uncertain, but may be due to its ability to inhibit local chemical mediators of the inflammatory response especially leukotriene synthesis in the GI mucosa. Action may be topical in terminal ileum and colon rather than systemic.
Note
Walasa 400mg Tablet manufactured by Wallace Pharmaceuticals Pvt Ltd.. Its generic name is Mesalazine. Walasa is availble in Nepal.
Farmaco Nepal drug index information on Walasa Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.